par Hougardy, Jean-Michel 
;de Jonge, Hylke;Kuypers, Dirk;Abramowicz, Daniel
Référence Transplantation, 93, 3, page (241-243)
Publication Publié, 2012-02
;de Jonge, Hylke;Kuypers, Dirk;Abramowicz, Daniel Référence Transplantation, 93, 3, page (241-243)
Publication Publié, 2012-02
Article révisé par les pairs
| Résumé : | Nonadherence is a critical issue in transplantation. Recently, Astellas designed a once-daily-extended release formulation of tacrolimus (Tac). Despite initial reports showing bioequivalence of Tac once-daily (Advagraf) with the original formulation requiring twice-daily intake (Tac twice-daily, Prograf), several groups have now shown a sustained decrease in Tac exposure upon conversion from Prograf to Advagraf. Here, we discuss the possible reasons for this observation and how it could affect the expected benefits of Advagraf, and we comment on the fact that a similar lack of bioequivalence might prevail with generic immunosuppressive drugs. |
